Actuate halves upcoming IPO to just $22M, scaling back clinical plans for cancer drug

Actuate Therapeutics was already keeping its planned IPO on the modest side, but the cancer-focused biotech has now lowered those expectations even further.

The Texas- and Ireland-based company first announced in late May its intention to go public, and last week confirmed plans to offer 5.5 million shares of common stock priced somewhere between $8 and $10 apiece.